Publications by authors named "Mondini M"

Over the last decade, the annual Immunorad Conference, held under the joint auspicies of Gustave Roussy (Villejuif, France) and the Weill Cornell Medical College (New-York, USA) has aimed at exploring the latest advancements in the fields of tumor immunology and radiotherapy-immunotherapy combinations for the treatment of cancer. Gathering medical oncologists, radiation oncologists, physicians and researchers with esteemed expertise in these fields, the Immunorad Conference bridges the gap between preclinical outcomes and clinical opportunities. Thus, it paves a promising way toward optimizing radiotherapy-immunotherapy combinations and, from a broader perspective, improving therapeutic strategies for patients with cancer.

View Article and Find Full Text PDF

We recently demonstrated that a heterogeneous tumor irradiation strategy, combining high-dose and low-dose radiotherapy (RT) within the same tumor volume, can synergize with immunotherapy in mice. Our findings indicate that heterogeneous RT doses may promote the spatial diversification of the antitumor immune response. Spatial fractionation of the RT dose has the potential to enhance the therapeutic index of RT/IO combinations, particularly in scenarios where irradiating the entire tumor volume is unfeasible or excessively harmful to the patient.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how different doses of radiotherapy (RT) affect the tumor immune environment and explores a strategy that combines low dose RT (LDRT) with high dose RT (HDRT) to enhance anti-tumor responses.
  • Researchers conducted experiments on colorectal and breast cancer models in mice, finding that a technique called partial irradiation (PI) improved tumor control when paired with an immune treatment (anti-PD1).
  • Results showed that PI reshaped immune cells in the tumor, increasing their ability to fight cancer, while also suggesting that adding a certain drug (CXCR2 antagonist) alongside RT and immunotherapy can enhance tumor control and survival rates.
View Article and Find Full Text PDF

Radiotherapy (RT) triggers an immune response that contributes to antitumor effects. Induction of IFNβ is a key event in this immunogenicity of RT. We have previously shown that TRIM33, a chromatin reader, restrains IFNβ expression in Toll-like receptor-activated myeloid cells.

View Article and Find Full Text PDF

Purpose: Radiation-induced pneumopathy is the main dose-limiting factor in cases of chest radiation therapy. Macrophage infiltration is frequently observed in irradiated lung tissues and may participate in lung damage development. Radiation-induced lung fibrosis can be reproduced in rodent models using whole thorax irradiation but suffers from limits concerning the role played by unexposed lung volumes in damage development.

View Article and Find Full Text PDF
Article Synopsis
  • JAK2V617F is the most common genetic mutation in Philadelphia-negative chronic Myeloproliferative Neoplasms (MPNs), and researchers believe abnormalities in Chromosome 9 may influence the disease in patients with this mutation.
  • A specific group of MPN patients, called +9p patients, were found to have three copies of the JAK2 gene and nearby genes, leading to increased production of the immunosuppressive PD-L1 protein.
  • The study showed that these +9p patients have a distinct cancer profile, characterized by greater stem cell-like properties and an immune response that results in exhausted T cells, highlighting a complex interaction between +9p and JAK2V617F mutations.
View Article and Find Full Text PDF

Cisplatin chemoradiotherapy (CRT) is the established standard of care for managing locally advanced human papillomavirus-positive head/neck carcinoma. The typically young patients may suffer serious and long-time side effects caused by the treatment, such as dysphagia, and hearing loss. Thus, ensuring a satisfactory post-treatment quality of life is paramount.

View Article and Find Full Text PDF

. Severe radiation-induced lymphopenia occurs in 40% of patients treated for primary brain tumors and is an independent risk factor of poor survival outcomes. We developed anframework that estimates the radiation doses received by lymphocytes during volumetric modulated arc therapy brain irradiation.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the combination of atezolizumab (a PD-L1 inhibitor) and stereotactic body radiation therapy (SBRT) in patients with advanced colorectal cancer (CRC) as part of the SABR-PDL1 trial.
  • A group of 60 pretreated patients from five centers participated, receiving atezolizumab and follow-up SBRT, with a focus on measuring progression-free survival (PFS) and collecting immune profiling data.
  • Results showed a median overall survival of 8.4 months and a PFS of 1.4 months, with the treatment being relatively well-tolerated; some patients exhibited significant responses, including stable disease and a few partial or
View Article and Find Full Text PDF

Background: KRAS activating mutations are considered the most frequent oncogenic drivers and are correlated with radio-resistance in multiple cancers including non-small cell lung cancer (NSCLC) and colorectal cancer. Although KRAS was considered undruggable until recently, several KRAS inhibitors have recently reached clinical development. Among them, MRTX849 (Mirati Therapeutics) showed encouraging clinical outcomes for the treatment of selected patients with KRAS mutated NSCLC and colorectal cancers.

View Article and Find Full Text PDF
Article Synopsis
  • The paper advocates for integrating archaeology into discussions on human contributions to climate change, using Niche Construction Theory as a foundational framework.
  • It emphasizes the importance of incorporating diverse perspectives, particularly from the Global South and the Neotropics, to account for both human and environmental factors in climate discussions.
  • The authors analyze the mid-Holocene Hypsithermal period in southern South America to highlight archaeological insights and their implications for effective policymaking regarding climate change.
View Article and Find Full Text PDF

Radiation-induced toxicity of the digestive tract is a major clinical concern as many cancer survivors have received radiotherapy for tumours of the abdominopelvic area. The coordination and orchestration of a tissue's response to stress depend not only on the phenotype of the cells that make up the tissue but also on cell-cell interactions. The digestive system, i.

View Article and Find Full Text PDF
Article Synopsis
  • Radiation-induced lymphopenia (RIL) means that there are fewer lymphocytes, a type of white blood cell, in the blood after someone undergoes radiotherapy for cancer.
  • Combining radiotherapy with immunotherapy could help reduce RIL and make treatments work better together, but we don’t fully understand why RIL happens yet.
  • This review aims to explain RIL in detail, look at new research about it, and think about new ways to treat patients who are getting both radiotherapy and immunotherapy.
View Article and Find Full Text PDF

Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However, only a few RT-IT combinations have been tested successfully in patients with cancer, highlighting the urgent need for an improved understanding of the interaction between RT and IT in both preclinical and clinical scenarios. Every year since 2016, ImmunoRad gathers experts working at the interface between RT and IT to provide a forum for education and discussion, with the ultimate goal of fostering progress in the field at both preclinical and clinical levels.

View Article and Find Full Text PDF

Background: Irradiation (IR) and immune checkpoint inhibitor (ICI) combination is a promising treatment modality. However, local and distance treatment failure and resistance can occur. To counteract this resistance, several studies propose CD73, an ectoenzyme, as a potential target to improve the antitumor efficiency of IR and ICI.

View Article and Find Full Text PDF
Article Synopsis
  • Recent clinical trials have started exploring the use of metallic nanoparticles (NPs) in radiotherapy for locally advanced cervical cancers, but current planning doesn't consider NP concentrations in target areas.
  • A method was developed to assess the biological effects of NPs on radiation, involving a calibration phantom and advanced MRI techniques that quantified NP levels in four patients, compared against mass spectrometry results from biopsies.
  • The study showed that NPs can enhance the effects of radiotherapy by about 15% at a dose of 2 Gy, positively influencing local tumor control, suggesting a need to integrate NP effects into future radiotherapy treatment plans.
View Article and Find Full Text PDF

Circulating monocytes are recruited in damaged tissues to generate macrophages that modulate disease progression. Colony-stimulating factor-1 (CSF-1) promotes the generation of monocyte-derived macrophages, which involves caspase activation. Here, we demonstrate that activated caspase-3 and caspase-7 are located to the vicinity of the mitochondria in CSF1-treated human monocytes.

View Article and Find Full Text PDF

The use of ionizing radiation (IR) is a cornerstone for the treatment of cancer and radiotherapy (RT) is used in roughly 50% of cancer patients. It is now well established that RT exerts widespread effects on the tumor stroma, including the immune environment. Together with its deeply characterized effects on the lymphoid compartment, RT also deeply affects the myeloid cell compartment.

View Article and Find Full Text PDF

Despite major research and clinical efforts, lung cancer remains the leading cause of cancer-related death. While the delivery of conformal radiotherapy and image guidance of stereotactic body radiotherapy (SBRT) have revolutionized the treatment of early-stage non-small-cell lung cancer (NSCLC), additional research is needed to elucidate underlying mechanisms of resistance and identify novel therapeutic combinations. Clinical progress relies on the successful translation of pre-clinical work, which so far has not always yielded expected results.

View Article and Find Full Text PDF

Background: Transforming growth factor-beta (TGFβ) can limit the efficacy of cancer treatments, including radiotherapy (RT), by inducing an immunosuppressive tumor environment. The association of TGFβ with impaired T cell infiltration and antitumor immunity is known, but the mechanisms by which TGFβ participates in immune cell exclusion and limits the efficacy of antitumor therapies warrant further investigations.

Methods: We used the clinically relevant TGFβ receptor 2 (TGFβR2)-neutralizing antibody MT1 and the small molecule TGFβR1 inhibitor LY3200882 and evaluated their efficacy in combination with RT against murine orthotopic models of head and neck and lung cancer.

View Article and Find Full Text PDF

Purpose: Radiation-induced cellular senescence is a double-edged sword, acting as both a tumor suppression process limiting tumor proliferation, and a crucial process contributing to normal tissue injury. Endothelial cells play a role in normal tissue injury after radiation therapy. Recently, a study observed an accumulation of senescent endothelial cells (ECs) around radiation-induced lung focal lesions following stereotactic radiation injury in mice.

View Article and Find Full Text PDF

Background: Tumors rewire their metabolism to achieve robust anabolism and resistance against therapeutic interventions like cisplatin treatment. For example, a prolonged exposure to cisplatin causes downregulation of pyridoxal kinase (PDXK), the enzyme that generates the active vitamin B6, and upregulation of poly ADP-ribose (PAR) polymerase-1 (PARP1) activity that requires a supply of nicotinamide (vitamin B3) adenine dinucleotide. We investigated the impact of the levels of PDXK and PAR on the local immunosurveillance (ie, density of the antigen presenting cells and adaptive immune response by CD8 T lymphocytes) in two different tumor types.

View Article and Find Full Text PDF

Chemoradiotherapy is considered an immunogenic anticancer treatment. Data obtained during the course of chemoradiotherapy treatment of patients with cervical cancer show heterogeneous changes in the tumor immune landscape, highlighting the need for patient selection to rationally design successful combined immunotherapies. Blood-based biomarkers could be valuable to perform such stratification.

View Article and Find Full Text PDF

Purpose: Severe pneumonia and acute respiratory distress syndrome (ARDS) have been described in patients with severe coronavirus disease 2019 (COVID-19). Recently, early clinical data reported the feasibility of low doses of radiation therapy (RT) in the treatment of ARDS in patients with severe COVID-19. However, the involved mechanisms remained unknown.

View Article and Find Full Text PDF

Background: Long-lasting shared research databases are an important source of epidemiological information and can promote comparison between different healthcare services. Here we present PROSAFE, an advanced international research network in intensive care medicine, with the focus on assessing and improving the quality of care. The project involved 343 ICUs in seven countries.

View Article and Find Full Text PDF